For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

A North Carolina woman has filed a lawsuit in New Jersey federal court, claiming that her use of the diabetes medication ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” says Dr. Joseph Rizzo, professor of ophthalmology at Harvard Medical School ...

However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve.

2025.0349. “Therefore, our study used the TriNetX global electronic health registry to assess the potential risk of NAION among patients with diabetes, using an alternative approach designed to ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

The researchers tracked nearly 175,000 patients with diabetes who received semaglutide -- the active ingredient in Ozempic and other Novo products -- and the same number of patients with diabetes ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...